233 related articles for article (PubMed ID: 30194476)
21. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
[TBL] [Abstract][Full Text] [Related]
22. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
23. Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.
Lindström E; Rizoska B; Henderson I; Terelius Y; Jerling M; Edenius C; Grabowska U
J Transl Med; 2018 May; 16(1):125. PubMed ID: 29743078
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of cathepsin K for treatment of osteoporosis.
Boonen S; Rosenberg E; Claessens F; Vanderschueren D; Papapoulos S
Curr Osteoporos Rep; 2012 Mar; 10(1):73-9. PubMed ID: 22228398
[TBL] [Abstract][Full Text] [Related]
25. [Cathepsin K antagonists: preclinical and clinical data].
Gamsjäger M; Resch H
Wien Med Wochenschr; 2015 Feb; 165(3-4):65-70. PubMed ID: 25572547
[TBL] [Abstract][Full Text] [Related]
26. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
Lark MW; Stroup GB; James IE; Dodds RA; Hwang SM; Blake SM; Lechowska BA; Hoffman SJ; Smith BR; Kapadia R; Liang X; Erhard K; Ru Y; Dong X; Marquis RW; Veber D; Gowen M
Bone; 2002 May; 30(5):746-53. PubMed ID: 11996914
[TBL] [Abstract][Full Text] [Related]
27. Investigation of osteoclast cathepsin K activity in osteoclastogenesis and bone loss using a set of chemical reagents.
Janiszewski T; Kołt S; Ciastoń I; Vizovisek M; Poręba M; Turk B; Drąg M; Kozieł J; Kasperkiewicz P
Cell Chem Biol; 2023 Feb; 30(2):159-174.e8. PubMed ID: 36696904
[TBL] [Abstract][Full Text] [Related]
28. Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
Duong LT; Clark S; Pickarski M; Giezek H; Cohn D; Massaad R; Stoch SA
Osteoporos Int; 2022 Oct; 33(10):2165-2175. PubMed ID: 35711006
[TBL] [Abstract][Full Text] [Related]
29. Different cysteine proteinases involved in bone resorption and osteoclast formation.
Brage M; Abrahamson M; Lindström V; Grubb A; Lerner UH
Calcif Tissue Int; 2005 Jun; 76(6):439-47. PubMed ID: 15906014
[TBL] [Abstract][Full Text] [Related]
30. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.
Stoch SA; Zajic S; Stone JA; Miller DL; van Bortel L; Lasseter KC; Pramanik B; Cilissen C; Liu Q; Liu L; Scott BB; Panebianco D; Ding Y; Gottesdiener K; Wagner JA
Br J Clin Pharmacol; 2013 May; 75(5):1240-54. PubMed ID: 23013236
[TBL] [Abstract][Full Text] [Related]
31. Effects of Long-Term Odanacatib Treatment on Bone Gene Expression in Ovariectomized Adult Rhesus Monkeys: Differentiation From Alendronate.
Muise ES; Podtelezhnikov AA; Pickarski M; Loboda A; Tan Y; Hu G; Thomspon JR; Duong le T
J Bone Miner Res; 2016 Apr; 31(4):839-51. PubMed ID: 26587671
[TBL] [Abstract][Full Text] [Related]
32. Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis.
Helali AM; Iti FM; Mohamed IN
Curr Drug Targets; 2013 Dec; 14(13):1591-600. PubMed ID: 23957815
[TBL] [Abstract][Full Text] [Related]
33. A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.
Robichaud J; Oballa R; Prasit P; Falgueyret JP; Percival MD; Wesolowski G; Rodan SB; Kimmel D; Johnson C; Bryant C; Venkatraman S; Setti E; Mendonca R; Palmer JT
J Med Chem; 2003 Aug; 46(17):3709-27. PubMed ID: 12904076
[TBL] [Abstract][Full Text] [Related]
34. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption.
Wilson SR; Peters C; Saftig P; Brömme D
J Biol Chem; 2009 Jan; 284(4):2584-92. PubMed ID: 19028686
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys.
Pennypacker BL; Chen CM; Zheng H; Shih MS; Belfast M; Samadfam R; Duong LT
J Bone Miner Res; 2014 Aug; 29(8):1847-58. PubMed ID: 24591096
[TBL] [Abstract][Full Text] [Related]
36. Steering the osteoclast through the demineralization-collagenolysis balance.
Søe K; Merrild DM; Delaissé JM
Bone; 2013 Sep; 56(1):191-8. PubMed ID: 23777960
[TBL] [Abstract][Full Text] [Related]
37. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
[TBL] [Abstract][Full Text] [Related]
38. Advances in the discovery of cathepsin K inhibitors on bone resorption.
Lu J; Wang M; Wang Z; Fu Z; Lu A; Zhang G
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):890-904. PubMed ID: 29723068
[TBL] [Abstract][Full Text] [Related]
39. Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.
Drake MT; Clarke BL; Oursler MJ; Khosla S
Endocr Rev; 2017 Aug; 38(4):325-350. PubMed ID: 28651365
[TBL] [Abstract][Full Text] [Related]
40. Identification of mouse cathepsin K structural elements that regulate the potency of odanacatib.
Law S; Andrault PM; Aguda AH; Nguyen NT; Kruglyak N; Brayer GD; Brömme D
Biochem J; 2017 Feb; 474(5):851-864. PubMed ID: 28049758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
